13 July 2026 • 2 minute read
DLA Piper advises FONAR Corporation on completed going-private merger
DLA Piper advised FONAR Corporation (FONAR), a medical imaging company, on its completed going-private merger with FONAR Acquisition Sub, Inc., effective June 3, 2026. As a result of the transaction, FONAR became a wholly owned subsidiary of FONAR, LLC.
“This transaction marks an important milestone in FONAR’s evolution,” said Timothy Damadian, Chief Executive Officer of FONAR. “DLA Piper’s guidance, experience, and unwavering commitment were instrumental in helping us successfully navigate this transaction and achieve an outstanding outcome.”
The DLA Piper deal team was co-led by Partners Joshua Kaye (Miami) and Jon Venick (New York) and included Partners Paolo Morante (New York) and Ronald Brown (Wilmington), as well as Associates Clara Knapp (San Diego), Nicholas Young (Phoenix), Parker Justi (Wilmington), and Sofia Puerto (Miami).
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 16 consecutive years by Mergermarket.
With more than 400 life sciences professionals worldwide, DLA Piper delivers seamless, tailored solutions across every stage of the business lifecycle. Our team includes medical doctors, PhDs, and industry veterans who bring extensive scientific and legal knowledge and experience to every challenge. We combine modern insights with an expansive geographic footprint to help clients anticipate risk, maximize opportunity, and stay ahead in a rapidly evolving landscape. Whether navigating complex regulations or defending innovation, we work as one—offering bold, agile strategies, and value-added counsel that keep science on your side.
“This transaction marks an important milestone in FONAR’s evolution,” said Timothy Damadian, Chief Executive Officer of FONAR. “DLA Piper’s guidance, experience, and unwavering commitment were instrumental in helping us successfully navigate this transaction and achieve an outstanding outcome.”
The DLA Piper deal team was co-led by Partners Joshua Kaye (Miami) and Jon Venick (New York) and included Partners Paolo Morante (New York) and Ronald Brown (Wilmington), as well as Associates Clara Knapp (San Diego), Nicholas Young (Phoenix), Parker Justi (Wilmington), and Sofia Puerto (Miami).
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 16 consecutive years by Mergermarket.
With more than 400 life sciences professionals worldwide, DLA Piper delivers seamless, tailored solutions across every stage of the business lifecycle. Our team includes medical doctors, PhDs, and industry veterans who bring extensive scientific and legal knowledge and experience to every challenge. We combine modern insights with an expansive geographic footprint to help clients anticipate risk, maximize opportunity, and stay ahead in a rapidly evolving landscape. Whether navigating complex regulations or defending innovation, we work as one—offering bold, agile strategies, and value-added counsel that keep science on your side.